Table 3.

3-(4,5-Dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2- (4-sulfophenyl)-2H-tetrazolium, inner salt cytotoxicity data

Cell lineTumor typeO5-methyl psorospermin (IC50, μmol/L)
2′R,3′R2′R,3′S2′S,3′R2′S,3′S
Solid tumors
    HeLaCervical, adenocarcinoma0.390 (1)*2.500 (2)3.200 (3)4.450 (4)
    MCF-7Breast, adenocarcinoma0.430 (1)0.570 (3)0.550 (2)2.720 (4)
    MCF-7/DOX (doxorubicin resistant)Breast, adenocarcinoma0.190 (1)0.690 (3)0.550 (2)2.220 (4)
    DU 145Prostate, brain metastasis0.230 (1)0.670 (3)0.570 (2)2.510 (4)
    MiaPaCa-2Pancreas0.100 (1)0.360 (2)0.380 (3)1.180 (4)
    H522Non–small cell lung0.280 (1)1.350 (3)0.770 (2)2.770 (4)
Leukemias
    HL60Acute promyelocytic leukemia0.016 (3)0.014 (2)0.009 (1)0.021 (4)
    HL60/AR (Adriamycin resistant)Acute promyelocytic leukemia0.013 (2)0.012 (1)0.016 (3)0.022 (4)
    K562Chronic myelogenous leukemia0.054 (1)0.286 (3)0.169 (2)0.595 (4)
    K562/R (daunorubicin resistant)Chronic myelogenous leukemia0.036 (1)0.207 (3)0.100 (2)0.329 (4)
    8226Multiple myeloma0.072 (1)0.345 (3)0.221 (2)0.494 (4)
    8226/DOX1V (topoisomerase II mediated)Multiple myeloma0.097 (1)0.366 (3)0.280 (2)1.100 (4)
    8226/DOX40Multiple myeloma0.037 (1)0.229 (3)0.174 (2)0.335 (4)
Lymphomas
    GrantaMantle cell lymphoma0.005 (1)0.050 (3)0.031 (2)0.071 (4)
    NCEB-1Non-Hodgkin's lymphoma0.051 (3)0.038 (1)0.047 (2)0.110 (4)
    U937Histiocytic lymphoma0.035 (1)0.260 (3)0.190 (2)0.570 (4)
  • * Number in parentheses indicates ranking among the four enantiomers.